Literature DB >> 32272494

Nonresearch Pharmaceutical Industry Payments to Oncology Physician Editors.

Waqas Haque1, Maria Alvarenga2, David Hsiehchen3.   

Abstract

Journal editors are gatekeepers of knowledge, and pharmaceutical industry payments to oncology editors have not been previously characterized. We performed a cross-sectional study of nonresearch industry payments to editors of 26 oncology research journals. A total of 433 editors were eligible for inclusion in the CMS Open Payments database from 2013 to 2018. A total of 80% of eligible editors had nonresearch payments, and the mean value of payments per editor was $106,778, which has increased over time. Only 5 out of 26 journals disclosed editor conflicts of interest and 3 of these journals reported at least one editor with no nonresearch industry payments but were found to have nonresearch payments. There was a positive correlation between journal impact factor and the average payment per editor for each journal. Our study shows the high prevalence and lack of transparency of nonresearch industry payments to oncology editors. Higher impact journals appear to be associated with greater nonresearch industry payments. © AlphaMed Press 2020.

Entities:  

Mesh:

Year:  2020        PMID: 32272494      PMCID: PMC7288645          DOI: 10.1634/theoncologist.2019-0828

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  7 in total

1.  The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials.

Authors:  Tatiana Goberstein Lerner; Michele da Costa Miranda; Andrea Thaumaturgo Lera; Aline Ueda; Bruna Briones; Auro Del Giglio; Rachel Riechelmann
Journal:  Contemp Clin Trials       Date:  2012-06-01       Impact factor: 2.226

2.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.

Authors:  Peter Q Eichacker; Charles Natanson; Robert L Danner
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

3.  Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.

Authors:  Deborah C Marshall; Beverly Moy; Madeleine E Jackson; Tim K Mackey; Jona A Hattangadi-Gluth
Journal:  J Natl Cancer Inst       Date:  2016-07-07       Impact factor: 13.506

4.  Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries.

Authors:  Aaron P Mitchell; Aaron N Winn; Stacie B Dusetzina
Journal:  JAMA Intern Med       Date:  2018-06-01       Impact factor: 21.873

5.  A randomized study of how physicians interpret research funding disclosures.

Authors:  Aaron S Kesselheim; Christopher T Robertson; Jessica A Myers; Susannah L Rose; Victoria Gillet; Kathryn M Ross; Robert J Glynn; Steven Joffe; Jerry Avorn
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

6.  Conflicts of interest of editors of medical journals.

Authors:  Waqas Haque; Abu Minhajuddin; Arjun Gupta; Deepak Agrawal
Journal:  PLoS One       Date:  2018-05-18       Impact factor: 3.240

7.  Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study.

Authors:  Jessica J Liu; Chaim M Bell; John J Matelski; Allan S Detsky; Peter Cram
Journal:  BMJ       Date:  2017-10-26
  7 in total
  3 in total

1.  Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review.

Authors:  Adrian M J Pokorny; Alice Fabbri; Lisa A Bero; Ray Moynihan; Barbara J Mintzes
Journal:  Br J Cancer       Date:  2021-10-01       Impact factor: 9.075

2.  A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough.

Authors:  Joel Lexchin; Adriane Fugh-Berman
Journal:  J Gen Intern Med       Date:  2021-03-10       Impact factor: 6.473

3.  How aging of the global population is changing oncology.

Authors:  Yan Fei Gu; Frank P Lin; Richard J Epstein
Journal:  Ecancermedicalscience       Date:  2021-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.